Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jingrui Jiang

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2011
Matrix metalloproteinase-8 is overexpressed in Waldenström's macroglobulinemia cells, and specific inhibition of this metalloproteinase blocks release of soluble CD27Yangsheng Zhou, Xia Liu, Lian Xu, et al.
Frontiers in Neuroscience|June 29, 2023
Development of a synchronous recording and photo-stimulating electrode in multiple brain neuronsQingping Zhang, Wei Jing, Shiping Wu, et al.
Gastroenterology|November 8, 2006
Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivityEllen Weisberg, Renee D Wright, Jingrui Jiang, et al.
Molecular Cancer Therapeutics|July 11, 2007
Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cellsEllen Weisberg, Andrew L Kung, Renee D Wright, et al.
Blood|January 11, 2008
Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cellsEllen Weisberg, Lolita Banerji, Renee D Wright, et al.
Cancer Biology & Therapy|May 15, 2007
Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitorsYuki Yuza, Karen A Glatt, Jingrui Jiang, et al.
Blood|October 28, 2006
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemiasEllen Weisberg, Laurie Catley, Renee D Wright, et al.
Molecular Cancer Therapeutics|September 3, 2010
Discovery and characterization of novel mutant FLT3 kinase inhibitorsEllen Weisberg, Hwan Geun Choi, Rosemary Barrett, et al.
Blood|June 5, 2004
Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AMLJingrui Jiang, J Guillermo Paez, Jeffrey C Lee, et al.
Blood|September 30, 2008
Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cellsEllen Weisberg, Johannes Roesel, Guido Bold, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2011
Matrix metalloproteinase-8 is overexpressed in Waldenström's macroglobulinemia cells, and specific inhibition of this metalloproteinase blocks release of soluble CD27Yangsheng Zhou, Xia Liu, Lian Xu, et al.
Frontiers in Neuroscience|June 29, 2023
Development of a synchronous recording and photo-stimulating electrode in multiple brain neuronsQingping Zhang, Wei Jing, Shiping Wu, et al.
Gastroenterology|November 8, 2006
Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivityEllen Weisberg, Renee D Wright, Jingrui Jiang, et al.
Molecular Cancer Therapeutics|July 11, 2007
Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cellsEllen Weisberg, Andrew L Kung, Renee D Wright, et al.
Blood|January 11, 2008
Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cellsEllen Weisberg, Lolita Banerji, Renee D Wright, et al.
Cancer Biology & Therapy|May 15, 2007
Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitorsYuki Yuza, Karen A Glatt, Jingrui Jiang, et al.
Blood|October 28, 2006
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemiasEllen Weisberg, Laurie Catley, Renee D Wright, et al.
Molecular Cancer Therapeutics|September 3, 2010
Discovery and characterization of novel mutant FLT3 kinase inhibitorsEllen Weisberg, Hwan Geun Choi, Rosemary Barrett, et al.
Blood|June 5, 2004
Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AMLJingrui Jiang, J Guillermo Paez, Jeffrey C Lee, et al.
Blood|September 30, 2008
Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cellsEllen Weisberg, Johannes Roesel, Guido Bold, et al.
Pageof 3